Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) Research & Development: 2020-2025

Historic Research & Development for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Sep 2025 value amounting to $3.9 million.

  • Insight Molecular Diagnostics' Research & Development rose 37.66% to $3.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.3 million, marking a year-over-year increase of 21.83%. This contributed to the annual value of $9.8 million for FY2024, which is 5.86% up from last year.
  • Insight Molecular Diagnostics' Research & Development amounted to $3.9 million in Q3 2025, which was up 18.20% from $3.3 million recorded in Q2 2025.
  • Insight Molecular Diagnostics' 5-year Research & Development high stood at $5.1 million for Q1 2022, and its period low was $1.4 million during Q4 2022.
  • Its 3-year average for Research & Development is $2.7 million, with a median of $2.5 million in 2024.
  • Per our database at Business Quant, Insight Molecular Diagnostics' Research & Development surged by 155.06% in 2021 and then slumped by 69.98% in 2022.
  • Quarterly analysis of 5 years shows Insight Molecular Diagnostics' Research & Development stood at $4.6 million in 2021, then slumped by 69.98% to $1.4 million in 2022, then spiked by 84.83% to $2.5 million in 2023, then decreased by 11.39% to $2.3 million in 2024, then skyrocketed by 37.66% to $3.9 million in 2025.
  • Its Research & Development was $3.9 million in Q3 2025, compared to $3.3 million in Q2 2025 and $2.9 million in Q1 2025.